Diagnosis and Treatment > Intervention > Lymphadenectomy
You are looking at 1 - 5 of 5 items
Search for other papers by Haruyuki Ohsugi in
Google Scholar
PubMed
Search for other papers by Nae Takizawa in
Google Scholar
PubMed
Search for other papers by Hidefumi Kinoshita in
Google Scholar
PubMed
Search for other papers by Tadashi Matsuda in
Google Scholar
PubMed
Summary
A 21-year-old woman was referred to our hospital to treat bilateral pheochromocytomas (PCCs) after a diagnosis of multiple endocrine neoplasia type 2A (MEN2A). We performed bilateral laparoscopic adrenalectomy. One year after the operation, urinary fractionated metanephrines in 24-h urine increased. MRI showed a 30 mm tumor on the interaortocaval region and 123I-MIBG concentrated in this area. We excised the tumor and performed para-aortic lymphadenectomy. Histopathologic examination confirmed a PCC arising from ectopic adrenal tissue. Urinary fractionated metanephrines in 24-h urine declined to basal levels immediately after the operation. We detected no recurrence of paraganglioma or PCC for 5 years after the treatment.
Learning points:
-
Most ectopic adrenal tissue is associated with no symptoms and contains only the adrenal cortex.
-
Adrenocortical tumors sometimes arise from ectopic adrenal tissues similarly to in the normal adrenal gland.
-
PCC arising from ectopic adrenal tissue occurs infrequently.
-
MEN2-related PCC is accompanied by adrenal medullary hyperplasia, which might be part of tumorigenesis.
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Dimitra Rontogianni in
Google Scholar
PubMed
Search for other papers by Constantine Stratakis in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Summary
Parathyroid carcinoma is an extremely rare endocrine malignancy that accounts for less than 1% of cases of primary hyperparathyroidism. We report a 44-year-old woman who presented with fatigue and diffuse bone pain. Laboratory findings revealed highly elevated serum calcium and parathyroid hormone (PTH) levels and a 4.5 × 3 × 2.5 cm cystic lesion in the lower pole of the right thyroid lobe that was shown histologically to be a parathyroid carcinoma. Ten years later, the patient developed brain and pulmonary metastases and recurrence of PTH-related hypercalcemia. Treatment of hypercalcemia along with localized radiotherapy and various chemotherapy regimens failed to induce a biochemical or radiological response. In conclusion, parathyroid carcinoma is a rare neoplasia that may develop metastases even after prolonged follow-up, for which there is no evidence-based treatment besides surgery. Different chemotherapeutic schemes did not prove to be of any benefit in our case highlighting the need for registering such patients to better understand tumor biology and develop specific treatment.
Learning points:
-
Metastases can develop many years after parathyroid cancer diagnosis.
-
Surgery is the only curative treatment for parathyroid carcinoma.
-
Chemotherapy and radiotherapy prove to be ineffective in parathyroid cancer treatment.
-
Patient registering is required in order to delineate underlining pathology and offer specific treatment.
Search for other papers by Jerena Manoharan in
Google Scholar
PubMed
Search for other papers by Caroline L Lopez in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Dresden, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, National Center for Tumor Diseases (NCT), Dresden, Germany
Search for other papers by Karl Hackmann in
Google Scholar
PubMed
Search for other papers by Max B Albers in
Google Scholar
PubMed
Search for other papers by Anika Pehl in
Google Scholar
PubMed
Search for other papers by Peter H Kann in
Google Scholar
PubMed
Search for other papers by Emily P Slater in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Dresden, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, National Center for Tumor Diseases (NCT), Dresden, Germany
Search for other papers by Evelin Schröck in
Google Scholar
PubMed
Search for other papers by Detlef K Bartsch in
Google Scholar
PubMed
Summary
We report about a young female who developed an unusual and an aggressive phenotype of the MEN1 syndrome characterized by the development of a pHPT, malignant non-functioning pancreatic and duodenal neuroendocrine neoplasias, a pituitary adenoma, a non-functioning adrenal adenoma and also a malignant jejunal NET at the age of 37 years. Initial Sanger sequencing could not detect a germline mutation of the MEN1 gene, but next generation sequencing and MPLA revealed a deletion of the MEN1 gene ranging between 7.6 and 25.9 kb. Small intestine neuroendocrine neoplasias (SI-NENs) are currently not considered to be a part of the phenotype of the MEN1-syndrome. In our patient the SI-NENs were detected during follow-up imaging on Ga68-Dotatoc PET/CT and could be completely resected. Although SI-NENs are extremely rare, these tumors should also be considered in MEN1 patients. Whether an aggressive phenotype or the occurrence of SI-NENs in MEN1 are more likely associated with large deletions of the gene warrants further investigation.
Learning points
-
Our patient presents an extraordinary course of disease.
-
Although SI-NENs are extremely rare, these tumors should also be considered in MEN1 patients, besides the typical MEN1 associated tumors.
-
This case reports indicate that in some cases conventional mutation analysis of MEN1 patients should be supplemented by the search for larger gene deletions with modern techniques, if no germline mutation could be identified by Sanger sequencing.
Search for other papers by Julien Ducry in
Google Scholar
PubMed
Search for other papers by Fulgencio Gomez in
Google Scholar
PubMed
Search for other papers by John O Prior in
Google Scholar
PubMed
Search for other papers by Ariane Boubaker in
Google Scholar
PubMed
Search for other papers by Maurice Matter in
Google Scholar
PubMed
Search for other papers by Matteo Monti in
Google Scholar
PubMed
Search for other papers by Yan Pu in
Google Scholar
PubMed
Search for other papers by Nelly Pitteloud in
Google Scholar
PubMed
Search for other papers by Luc Portmann in
Google Scholar
PubMed
Summary
Ectopic ACTH Cushing's syndrome (EAS) is often caused by neuroendocrine tumors (NETs) of lungs, pancreas, thymus, and other less frequent locations. Localizing the source of ACTH can be challenging. A 64-year-old man presented with rapidly progressing fatigue, muscular weakness, and dyspnea. He was in poor condition and showed facial redness, proximal amyotrophy, and bruises. Laboratory disclosed hypokalemia, metabolic alkalosis, and markedly elevated ACTH and cortisol levels. Pituitary was normal on magnetic resonance imaging (MRI), and bilateral inferior petrosal sinus blood sampling with corticotropin-releasing hormone stimulation showed no significant central-to-periphery gradient of ACTH. Head and neck, thoracic and abdominal computerized tomography (CT), MRI, somatostatin receptor scintigraphy (SSRS), and 18F-deoxyglucose-positron emission tomography (FDG-PET) failed to identify the primary tumor. 18F-dihydroxyphenylalanine (F-DOPA)-PET/CT unveiled a 20-mm nodule in the jejunum and a metastatic lymph node. Segmental jejunum resection showed two adjacent NETs, measuring 2.0 and 0.5 cm with a peritoneal metastasis. The largest tumor expressed ACTH in 30% of cells. Following surgery, after a transient adrenal insufficiency, ACTH and cortisol levels returned to normal values and remain normal over a follow-up of 26 months. Small mid-gut NETs are difficult to localize on CT or MRI, and require metabolic imaging. Owing to low mitotic activity, NETs are generally poor candidates for FDG-PET, whereas SSRS shows poor sensitivity in EAS due to intrinsically low tumor concentration of type-2 somatostatin receptors (SST2) or to receptor down regulation by excess cortisol. However, F-DOPA-PET, which is related to amine precursor uptake by NETs, has been reported to have high positive predictive value for occult EAS despite low sensitivity, and constitutes a useful alternative to more conventional methods of tumor localization.
Learning points
-
Uncontrolled high cortisol levels in EAS can be lethal if untreated.
-
Surgical excision is the keystone of NETs treatment, thus tumor localization is crucial.
-
Most cases of EAS are caused by NETs, which are located mainly in the lungs. However, small gut NETs are elusive to conventional imaging and require metabolic imaging for detection.
-
FDG-PET, based on tumor high metabolic rate, may not detect NETs that have low mitotic activity. SSRS may also fail, due to absent or low concentration of SST2, which may be down regulated by excess cortisol.
-
F-DOPA-PET, based on amine-precursor uptake, can be a useful method to localize the occult source of ACTH in EAS when other methods have failed.
Search for other papers by K Nadarasa in
Google Scholar
PubMed
Search for other papers by M Bailey in
Google Scholar
PubMed
Search for other papers by H Chahal in
Google Scholar
PubMed
Search for other papers by O Raja in
Google Scholar
PubMed
Search for other papers by R Bhat in
Google Scholar
PubMed
Search for other papers by C Gayle in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
Search for other papers by M R Druce in
Google Scholar
PubMed
Summary
We present the case of a patient with metastatic parathyroid carcinoma whose hypercalcaemia was medically managed through two pregnancies. The diagnosis was made when the patient presented with chronic knee pain and radiological findings consistent with a brown tumour, at the age of 30. Her corrected calcium and parathyroid hormone (PTH) levels were significantly elevated. Following localisation studies, a right parathyroidectomy was performed with histology revealing parathyroid carcinoma, adherent to thyroid tissue. Aged 33, following biochemical recurrence of disease, the patient underwent a second operation. A subsequent CT and FDG–PET revealed bibasal pulmonary metastases. Aged 35, the patient was referred to our unit for treatment of persistent hypercalcaemia. The focus of treatment at this time was debulking metastatic disease using radiofrequency ablation. Despite advice to the contrary, the patient conceived twice while taking cinacalcet. Even though there are limited available data regarding the use of cinacalcet in pregnancy, both pregnancies continued to term with the delivery of healthy infants, using intensive medical management for persistent hypercalcaemia.
Learning points
-
Parathyroid carcinoma is a rare cause of primary hyperparathyroidism.
-
Hypercalcaemia during pregnancy can result in significant complications for both the mother and the foetus.
-
The use of high-dose cinacalcet in pregnancy has been shown, in this case, to aid in the management of resistant hypercalcaemia without teratogenicity.
